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Sir,
Erdheim Chester disease (ECD) is a rare, non-Langerhans' cell histiocytic neoplastic disorder that usually presents in patients in their fifties. ECD often presents as a multi-system macrophagic infiltration and common sites of involvement are the central nervous system, cardiovascular system, respiratory system, retroperitoneum, and skin. Extra-skeletal involvement is usually responsible for death due to secondary complications and ECD has had until recently an extremely poor prognosis (vide infra), with less than half of patients surviving three years (1).
The exact aetiology of ECD is unknown, but recent molecular studies have shown that that over half of the cases contain a BRAF V600 mutation (2). However, Diamond et al. recently reported a single case of ECD with an NRAS codon 61 substitution in the absence of a BRAF mutation (3). Here we report the second case of ECD with an NRAS mutation identified through review of the pathology archives:
we identified a case of a 77 year-old retired man with multiple co-morbidities who presented with progressive bone pain around the right knee. Radiographs showed areas of increased density in both tibiae and the right femur, but no widespread bony lesions. In addition, T1-weighted magnetic resonance imaging showed confluent areas of abnormal marrow signal in the femur and tibia, with heterogeneous fat adjacent to the femoral lesion (Figure 1 ). Due to the patient's frailty, serial imaging was not performed.
Microscopic examination of a needle biopsy specimen taken from the presenting bony lesion in the right tibia showed diffuse chronic macrophagic infiltration of bone with associated bone remodelling ( Figure 1 ). In spite of presentation with only localised disease, ECD was suggested. The patient did not receive active treatment for ECD due to co-morbidities, including bladder cancer.
To characterise further the abnormal infiltrate in bone, a next generation sequencing approach was used to examine mutations in common oncogenes. 10ng of DNA was extracted from three 10µm formalin-fixed paraffin-embedded sections from the needle biopsy, and examination of the haematoxylin and eosin-stained section showed that the lesion had a neoplastic cell content of approximately 50%. The A molecular diagnosis can be valuable for providing a robust objective diagnosis and is particularly useful in this rare disease where the morphology can mimic a spectrum of reactive conditions. Genetic alterations in ECD are also important for guiding patient management because the identification of a BRAF V600E substitution in such patients, even with multisystemic disease which is refractory to first-line interferon-α treatment has been shown to respond to the BRAF inhibitor vemurafenib (4). In contrast, ECD harbouring an NRAS mutation would not be expected to respond to such targeted therapy. Although direct inhibition of NRAS has proven difficult, the downstream mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinases (PI3K) pathways are potential targets and MEK inhibitors, which act on the MAPK pathway, have been used successfully in NRAS-mutated melanoma and may therefore be useful in other NRAS-dependent neoplastic diseases.
This case highlights the value of being able to provide a robust tissue diagnosis in addition to identifying mutations that could be exploited for targeted therapy or in this case deciding not to provide a targeted therapy from which most cases of ECD would benefit. This report of the second NRAS mutation in ECD argues for the need for 
